Further, the highest frequency of TP53 deletion was identified in high-grade gliomas (HGG) (WHO grade III and IV) when compared to low-grade gliomas (LGG) (WHO grade I and II) (13/37 cases, 35.1% vs. 6/28 cases, 21.4% respectively); however, no association was observed between the presence of this alteration and WHO grading groups (p = 0.3535). Here, TP53 is linked to central nervous system cancer.